<DOC>
	<DOCNO>NCT02882347</DOCNO>
	<brief_summary>Post hepatectomy liver failure ( PHLF ) serious medical problem could lead patient death , however , definite treatment strategy establish . The liver regenerate organ possibility PHLF could reduce appropriate liver regeneration guarantee . Portal flow know important liver regeneration . Low portal flow induce proper regeneration , contrary , excessive flow increase shear stress hepatic sinusoid result liver failure . Various medication use malignant liver cirrhosis reduce portal pressure . Among , somatostatin use modulating portal flow reduce portal sinusoidal pressure . In study , investigator administrate somatostatin rate 3.5ug/kg/hour PHLF patient ( prothrombin time &lt; 50 % serum total bilirubin &gt; 2.9mg/dl liver resection ) recovery liver failure . For assessment recovery liver failure , investigator evaluate aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , serum total bilirubin prothrombin time periodically administration medication .</brief_summary>
	<brief_title>The Effect Somatostatin Treatment Post Hepatectomy Liver Failure ( PHLF )</brief_title>
	<detailed_description />
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>1 . Patients PHLF without regard primary disease . 2 . Ability provide write informed consent 1 . Concomitant surgery another intraabdominal organ . 2 . Severe renal disease require dialysis . 3 . Patients coagulation disorder take warfarin . 4 . Immunosuppressed patient patient autoimmune disorder . 5 . Women pregnant , breastfeed . 6 . Hypersensitivity somatostatin . 7 . Patients treat investigational product within 30 day consent obtain . 8 . Patients significantly reduce cognitive ability . 9 . Not eligible participate study discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>